Literature DB >> 20538338

Folylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia.

Guy J Leclerc1, Christopher Sanderson, Stephen Hunger, Meenakshi Devidas, Julio C Barredo.   

Abstract

Acute Lymphoblastic Leukemia (ALL) non-random fusions influence clinical outcome and alter the accumulation of MTX-PGs in vivo. Analysis of primary ALL samples uncovered subtype-specific patterns of folate gene expression. Using an FPGS-luciferase reporter gene assay, we determined that E2A-PBX1 and TEL-AML1 expression decreased FPGS transcription. ChIP assays uncovered HDAC1, AML1, mSin3A, E2F, and Rb interactions with the FPGS promoter region. We demonstrate that FPGS expression is epigenetically regulated through binding of selected ALL fusions to a multiprotein complex, which also controls the cell cycle dependence of FPGS expression. This study provides insights into the pharmacogenomics of MTX in ALL subtypes.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538338      PMCID: PMC2946984          DOI: 10.1016/j.leukres.2010.05.012

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  46 in total

1.  E2Fs up-regulate expression of genes involved in DNA replication, DNA repair and mitosis.

Authors:  Shirley Polager; Yael Kalma; Eli Berkovich; Doron Ginsberg
Journal:  Oncogene       Date:  2002-01-17       Impact factor: 9.867

Review 2.  Sibling rivalry in the E2F family.

Authors:  Jeffrey M Trimarchi; Jacqueline A Lees
Journal:  Nat Rev Mol Cell Biol       Date:  2002-01       Impact factor: 94.444

3.  Computer-assisted identification of cell cycle-related genes: new targets for E2F transcription factors.

Authors:  A E Kel; O V Kel-Margoulis; P J Farnham; S M Bartley; E Wingender; M Q Zhang
Journal:  J Mol Biol       Date:  2001-05-25       Impact factor: 5.469

Review 4.  The genetics of the E2F family of transcription factors: shared functions and unique roles.

Authors:  James DeGregori
Journal:  Biochim Biophys Acta       Date:  2002-06-21

5.  Folylpoly-gamma-glutamate synthetase gene mRNA splice variants and protein expression in primary human leukemia cells, cell lines, and normal human tissues.

Authors:  G J Leclerc; J C Barredo
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

6.  The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.

Authors:  V M Whitehead; C Payment; L Cooley; S J Lauer; D H Mahoney; J J Shuster; M J Vuchich; M L Bernstein; A T Look; D J Pullen; B Camitta
Journal:  Leukemia       Date:  2001-07       Impact factor: 11.528

Review 7.  Childhood acute lymphoblastic leukaemia--current status and future perspectives.

Authors:  C H Pui; D Campana; W E Evans
Journal:  Lancet Oncol       Date:  2001-10       Impact factor: 41.316

Review 8.  Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.

Authors:  S W Heibert; B Lutterbach; K Durst; L Wang; B Linggi; S Wu; L Wood; J Amann; D King; Y Hou
Journal:  Cancer Chemother Pharmacol       Date:  2001-08       Impact factor: 3.333

9.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.

Authors:  Eng-Juh Yeoh; Mary E Ross; Sheila A Shurtleff; W Kent Williams; Divyen Patel; Rami Mahfouz; Fred G Behm; Susana C Raimondi; Mary V Relling; Anami Patel; Cheng Cheng; Dario Campana; Dawn Wilkins; Xiaodong Zhou; Jinyan Li; Huiqing Liu; Ching-Hon Pui; William E Evans; Clayton Naeve; Limsoon Wong; James R Downing
Journal:  Cancer Cell       Date:  2002-03       Impact factor: 31.743

10.  Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.

Authors:  Adolfo A Ferrando; Donna S Neuberg; Jane Staunton; Mignon L Loh; Christine Huard; Susana C Raimondi; Fred G Behm; Ching Hon Pui; James R Downing; D Gary Gilliland; Eric S Lander; Todd R Golub; A Thomas Look
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

View more
  5 in total

1.  Mcl-1 downregulation leads to the heightened sensitivity exhibited by BCR-ABL positive ALL to induction of energy and ER-stress.

Authors:  Guy J Leclerc; Joanna DeSalvo; Jianfeng Du; Ningguo Gao; Gilles M Leclerc; Mark A Lehrman; Theodore J Lampidis; Julio C Barredo
Journal:  Leuk Res       Date:  2015-08-20       Impact factor: 3.156

2.  Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.

Authors:  Anna Wojtuszkiewicz; Godefridus J Peters; Nicole L van Woerden; Boas Dubbelman; Gabriele Escherich; Kjeld Schmiegelow; Edwin Sonneveld; Rob Pieters; Peter M van de Ven; Gerrit Jansen; Yehuda G Assaraf; Gertjan J L Kaspers; Jacqueline Cloos
Journal:  J Hematol Oncol       Date:  2015-05-29       Impact factor: 17.388

3.  Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia.

Authors:  Shuhua Zheng; Gilles M Leclerc; Bin Li; Ronan T Swords; Julio C Barredo
Journal:  Oncotarget       Date:  2017-12-31

4.  β-catenin promotes MTX resistance of leukemia cells by down-regulating FPGS expression via NF-κB.

Authors:  Shu-Guang Liu; Zhi-Xia Yue; Zhi-Gang Li; Rui-Dong Zhang; Hu-Yong Zheng; Xiao-Xi Zhao; Chao Gao
Journal:  Cancer Cell Int       Date:  2020-06-24       Impact factor: 5.722

5.  FPGS rs1544105 polymorphism is associated with treatment outcome in pediatric B-cell precursor acute lymphoblastic leukemia.

Authors:  Shu-Guang Liu; Chao Gao; Rui-Dong Zhang; Ying Jiao; Lei Cui; Wei-Jing Li; Zhen-Ping Chen; Min-Yuan Wu; Hu-Yong Zheng; Xiao-Xi Zhao; Zhi-Xia Yue; Zhi-Gang Li
Journal:  Cancer Cell Int       Date:  2013-10-29       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.